As we previously discussed (here and here), the biotech mergers and acquisitions market currently faces significant headwinds. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug...more
6/10/2025
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Corporate Governance ,
Department of Health and Human Services (HHS) ,
Food and Drug Administration (FDA) ,
Initial Public Offering (IPO) ,
Mergers ,
Pharmaceutical Industry ,
Securities and Exchange Commission (SEC) ,
Shareholders ,
Spinoffs ,
Tax Planning ,
Tax-Free Spin-Offs